ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Transdermal delivery of salvianolic acid B using thermosensitive hydrogel for the treatment of skin photoaging.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Intelligent transdermal nanoparticles as synergizing advanced delivery systems for precision therapeutics.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Salvianolic acid B (Sal B) exhibits great potential in treating skin photoaging. However, its therapeutic activity is severely hindered by poor skin permeability, making the preparation of a transdermal formulation an urgent need. To overcome this limitation, the microwave method was employed to prepare chitosan-coated gold nanoparticles (CS-Au NPs), and the preparation process was optimized for co-encapsulation of Sal B and CS-Au NPs with hyaluronic acid and Pluronic F-127 (CAS@HF). Subsequently, the microscopic morphology and transdermal drug release capabilities of CAS@HF were evaluated using transmission electron microscopy and Franz diffusion cells, respectively. It was found that CAS@HF exhibited a fluid state at 25 °C and underwent gelation at 36.3 °C, forming a porous structure and demonstrating excellent skin permeability and retention. Furthermore, a photoaging cell model was established, and its anti-photoaging activity in vitro was assessed through CCK-8 assays, scratch assays, β-galactosidase staining, and Western blot analysis. It revealed that CAS@HF promoted cell migration, alleviated cellular senescence, and reduced ROS levels, which were associated with the inhibition of the P53/P21 pathway and the promotion of NRF2 translocation. Finally, a photoaging mouse model was constructed to further validate the anti-photoaging potential of CAS@HF in vivo using H&E staining, Masson's trichrome staining, and ROS staining. The results showed that CAS@HF mitigated photoaging phenomena, increased collagen levels and reduced ROS levels. In conclusion, CAS@HF enhanced the transdermal delivery of Sal B and potentiated its therapeutic effect on skin photoaging. This discovery provided potential therapeutic strategies and theoretical support for clinical treatment of photoaging.
Indexed as
Identifiers
40579540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.